Investor to receive percentage of development program's proceeds
By Angela McDaniels
Tacoma, Wash., Oct. 25 - Omeros Corp. received $20 million from Vulcan Capital and issued warrants for 399,999 shares of common stock to the investor, according to a company news release.
Vulcan Capital received three five-year warrants with exercise prices of $20.00, $30.00 and $40.00 per share, respectively. Each warrant is exercisable for 133,333 shares.
The strike prices are premiums of 173.97%, 310.96% and 447.95%, respectively, to the closing price of the company's stock on Oct. 22.
The proceeds from the investment, along with a $5 million grant award from Washington state's Life Sciences Discovery Fund, will be used to support the advancement of the company's G protein-coupled receptor program.
Vulcan Capital and the Life Sciences Discovery Fund will receive a percentage of the net proceeds generated by the program. The blended percentage payable to Vulcan Capital and the fund is in the mid-teens with respect to the first approximately $1.5 billion of net proceeds and then 1% for net proceeds in excess of $1.5 billion.
Omeros is a Seattle-based biopharmaceutical company focused on inflammation and disorders of the central nervous system.
Issuer: | Omeros Corp.
|
Issue: | Cash investment plus three warrants for 133,333 shares each
|
Amount: | $20 million
|
Warrants: | For 399,999 shares
|
Warrant expiration: | Five years
|
Warrant strike prices: | $20.00 for 133,333 shares, $30.00 for 133,333 shares, $40.00 for 133,333 shares
|
Pricing date: | Oct. 25
|
Stock symbol: | Nasdaq: OMER
|
Stock price: | $7.30 at close Oct. 22
|
Market capitalization: | $168.89 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.